$0.91
-0.07 (-6.75%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ELUT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional · 12 observational · 7 with posted results
Held by 4 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, JANE STREET GROUP, LLC, Qube Research & Technologies Ltd) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| EluPro Antibiotic-Eluting BioEnvelope RegistryNCT06854081observationalAdverse Events/Complication Rates | — | Active, not recruiting | Combination product: EluPro Antibiotic-Eluting BioEnvelope | Cardiac Arrhythmias | 100 | Dec 2026 | ≤ 134 d | 2026-05-28 |
| Comparison of Participants Who Received a CanGaroo® Envelope, TYRX™ Envelope, or no Envelope During CIED ImplantationNCT04645173observationalBlinded Histologic Evaluation of Biopsies Taken from the Anterior and Posterior Capsule Wall | — | Completed | Device: CIED envelope | Cardiac Disease | 46 | 2023-10-31actual | — | 2024-01-09 |
| CanGaroo® Registry StudyNCT04846127observationalAssociation between participant characteristics and outcomes | — | Completed | Device: CanGaroo Envelope | Arrhythmias, Cardiac | 500 | 2023-04-17actual | — | 2025-05-15 |
| A Retrospective Breast Reconstruction StudyNCT04060134observationalOccurrence of Events | — | Completed | Other: SimpliDerm HADM, AlloDerm HADM, AlloMax HADM, FlexHD HADM, DermACELL HADM | Breast Cancer | 223 | 2022-03-14actual | — | 2024-02-14 |
| CIED Implantation in Low BMI PatientsNCT04299282Healing at incision siteRandomized · Open-label · Prevention | Not applicable | Withdrawnsponsor's stated reason: Postponed due to COVID-19 pandemic | Device: CanGaroo | Heart Diseases, Cardiac Disease | 0 | Dec 2021 | — | 2025-05-16 |
| Retrospective Experience Of CIED ImplantationNCT04351269results2022-05-18observationalNumber of Participants With Major Infection Post ProcedureStudy Protocol and Statistical Analysis Plan ↗ | — | Completed | Device: CanGaroo Envelope, TYRX Envelope | Cardiac Disease, Heart Failure, Coronary Artery Disease | 597 | 2021-06-30actual | — | 2023-07-21 |
| ViBone in Cervical and Lumbar Spine FusionNCT03425682results2025-03-04observationalFusion Rates Per Level Using the Bridwell Interbody Grading ScaleStudy Protocol and Statistical Analysis Plan ↗ | — | Completed | Other: ViBone | Spondylosis, Cervical Spondylosis, Spondylolisthesis, Herniated Nucleus Pulposus, Degenerative Disc Disease | 118 | 2021-01-15actual | — | 2025-03-04 |
| A Study Evaluating 3-Level OLIF Spine FusionNCT03896347observationalGraft Mineralization/Fusion | — | Withdrawnsponsor's stated reason: Lack of enrollment | Other: ViBone®, Demineralized Bone Matrix, Bone Morphogenetic Protein | Spondylolisthesis, Retrolisthesis, Degenerative Disc Disease | 0 | 2020-02-07actual | — | 2023-07-20 |
| A Study on the Use of CorMatrix® ECM® for Femoral Arterial ReconstructionNCT02418156results2020-02-11observationalDevice-Related Adverse EventsStudy Protocol and Statistical Analysis Plan ↗ | — | Completed | Device: CorMatrix ECM for Vascular Repair | Peripheral Vascular Disease | 38 | Mar 2018actual | — | 2023-07-21 |
| Obtain Additional Information on Use of CorMatrix ECM (Extracellular Matrix)NCT02073331results2019-10-04observationalProportion of Subjects With Device Related Adverse Events.Study Protocol ↗ | — | Completed | — | Coronary Disease | 1,420 | Dec 2017actual | — | 2023-07-21 |
| A Post Market Study on the Use of Cormatrix® Cangaroo ECM® (Extracellular Matrix) EnvelopeNCT02530970results2020-03-11observationalProportion of Subjects With ECM Related Adverse EventsStudy Protocol and Statistical Analysis Plan ↗ | — | Completed | — | Cardiovascular Disease | 1,025 | Dec 2017actual | — | 2023-07-21 |
| CorMatrix ECM for Carotid Repair Following Endarterectomy RegistryNCT01569594results2020-02-24observationalCarotid Procedure and Device Related Adverse Events to Determine Device PerformanceStudy Protocol and Statistical Analysis Plan ↗ | — | Completed | Device: CorMatrix ECM for Carotid Repair | Carotid Stenosis | 230 | 2016-12-31actual | — | 2023-07-21 |
| A Study to Obtain Additional Information on the Use of CorMatrix® CanGaroo ECM® EnvelopeNCT02418143observationalDevice Related Adverse Events | — | Withdrawn | Device: CorMatrix CanGaroo ECM Envelope | Coronary Disease | 0 | Jan 2016 | — | 2023-07-20 |
| Evaluation Of New Onset Postoperative Atrial FibrillationNCT01247974results2015-09-16Primary Safety EndpointRandomized · Single-masked · Prevention | Not applicable | Completed | Device: CorMatrix ECM for Pericardial Closure | Atrial Fibrillation New Onset | 439 | Dec 2012actual | — | 2023-07-27 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19